期刊
BIOTECHNOLOGY JOURNAL
卷 11, 期 4, 页码 497-506出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201500377
关键词
Bioreactor; Hydroxyproline-O-glycosylation; Perfusion culture; Plant cell culture; Recombinant protein
资金
- Arkansas Center for Plant-Powered Production through NSF RII Arkansas ASSET Initiative [EPS-1003970]
- National Institute of Health (NIH) [1R43GM093621-01]
- Arkansas Biosciences Institute, Arkansas Tobacco Settlement Proceeds Act
- Office Of The Director
- EPSCoR [1003970] Funding Source: National Science Foundation
Low-yield protein production remains the most significant economic hurdle with plant cell culture technology. Fusions of recombinant proteins with hydroxyproline-O-glycosylated designer glycopeptide tags have consistently boosted secreted protein yields. This prompted us to study the process development of this technology aiming to achieve productivity levels necessary for commercial viability. We used a tobacco BY-2 cell culture expressing EGFP as fusion with a glycopeptide tag comprised of 32 repeat of Ser-Pro dipeptide, or (SP)(32), to study cell growth and protein secretion, culture scale-up, and establishment of perfusion cultures for continuous production. The BY-2 cells accumulated low levels of cell biomass (approximate to 7.5 g DW/L) in Schenk & Hildebrandt medium, but secreted high yields of (SP)(32)-tagged EGFP (125 mg/L). Protein productivity of the cell culture has been stable for 6.0 years. The BY-2 cells cultured in a 5-L bioreactor similarly produced high secreted protein yield at 131 mg/L. Successful operation of a cell perfusion culture for 30 days was achieved under the perfusion rate of 0.25 and 0.5 day(-1), generating a protein volumetric productivity of 17.6 and 28.9 mg/day/L, respectively. This research demonstrates the great potential of the designer glycopeptide technology for use in commercial production of valuable proteins with plant cell cultures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据